Latest news

• End to middlemen rebates a major shift in US drug pricing

  Puts onus on pharma, which cites rebates as biggest barrier. The Trump administration plans to ban rebates paid by pharma to insurance middlemen, and instead wants to see them passed directly ... The changes fulfil promises made by President Trump last

• FDA takes aim at pharma’s biosimilar-delaying tactics

  The obstructive practices were referred to as ‘gaming’ in President Trump’s blueprint document which was unveiled earlier this year, as part of a package of measures that are aimed at ... Reference pricing is one of the measures being considered in

• Reference price bill tabled in US House and Senate

  Reference pricing is one of the proposals that has been put forward by Trump since he published a blueprint to reduce medicine prices earlier this year. ... due to high deductibles and co-insurance”, which is another of Trump’s proposals.

• Pfizer CEO reckons rebates will disappear, and that’s a positive

  Speaking on the company’s second-quarter results call, he said that eliminating rebates – one of the main themes of President Donald Trump’s blueprint for reducing drug pricing – would be ... Read’s comments came shortly after Pfizer’s much

• Trump attempts The Art of the Deal with pharma

  The President of the United States recently unveiled his long-awaited plan to lower prescription drug prices in America.Trump’s plan, called American Patients First, The Trump Administration Blueprint to ... Trump wants the rest of the world to pony up